急性冠状动脉综合征患者血清同型半胱氨酸与基质金属蛋白酶9及其抑制物浓度改变的意义

下载PDF

导出

作者郭炳彦张延军崔志宏李拥军

机构地区河北医科大第二医院心血管内科故城县医院心内科

出处《临床荟萃》 CAS 2009年第11期966-967,共2页 Clinical Focus

关键词冠状动脉疾病半胱氨酸基质金属蛋白酶9

参考文献6

1Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, intedeukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum tropeninI[J]. Clin Cardiol, 2005,28(4): 182-186.
2Fiotti N, Altamura N, Orlando C, et al. Metalloproteinases-2,-9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI[J]. Int J Cardiol,2008,127(3) :350-357.
3Fruchart JC,Nierman MC, Stroes ES, et al. New risk factor for atherosclerosis and patient risk assessment [J]. Circulation, 2004,109(23 Suppl 1) :Ⅲ 15-19.
4Rasouli ML, Nasir K, Blumenthal RS, et al. Plasma homocysteine predicts progression of atherosclerosis [ J ]. Atherosclerosis, 2005,181 ( 1 ): 159-165.
5Holven KB, Halvorsen B, Sehulz H, et al. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects[J]. Eur J Clin Invest, 2003,33 (7):555-560.
6Holven KB, Halvorsen B, Bjerkeli V, et al. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects [J]. Stroke, 2006,37 ( 7 ) : 1731- 1736.

临床荟萃

2009年第11期

内容加载中请稍等...